13 News & Press Releases found
Circassia Group PLC News
-
Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest
Circassia Pharmaceuticals plc, (“Circassia” or “the Company”; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement ...
-
Circassia Announces Duaklir US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US launch of Duaklir® for the maintenance treatment of chronic ...
-
Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces the appointment of Jonathan Emms to the newly-created role of Chief ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the ...
-
Circassia Announces FDA Approval of Duaklir for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration ...
-
Circassia Announces FDA Approval of Duaklir for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc ...
-
Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza from AstraZeneca
Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has issued a notice of option ...
-
Circassia Announces Duaklir New Drug Application (NDA) and Tudorza Supplemental NDA Accepted for Review by FDA
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the United States Food and Drug Administration (FDA) has ...
-
Circassia Announces Submission of Duaklir New Drug Application and Tudorza Supplemental New Drug Application in the United States
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or ...
-
Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® ...